Abstract
During the last decade, a greater focus has been given to impact of genetic variation in membrane transporters on the pharmacokinetics and toxicity of numerous therapeutic drugs. While the majority of transporter-related pharmacogenetic research has been in regards to classic genes encoding the outward-directed ATP-binding cassette (ABC) transporters, such as ABCB1 (Pglycoprotein), ABCC2 (MRP2), and ABCG2 (BCRP), more studies have been conducted in recent years evaluating genes encoding solute carriers (SLC) that mediate the cellular uptake of drugs, such as SLCO1B1 (OATP1B1) and SLC22A1 (OCT1). The distribution of ABC and SLC transporters in tissues key to pharmacokinetics, such as intestine (absorption), blood-brain-barrier (distribution), liver (metabolism), and kidneys (excretion), strongly suggests that genetic variation associated with changes in protein expression or function of these transporters may have a substantial impact on systemic drug exposure and toxicity. In this current article, we will review recent advances in understanding the contribution of critical ABC and SLC transporters to interindividual pharmacokinetic and dynamic variability of substrate drugs.
Current Pharmaceutical Design
Title: Pharmacogenetics of Drug Transporters
Volume: 16 Issue: 2
Author(s): R. M. Franke, E. R. Gardner and A. Sparreboom
Affiliation:
Abstract: During the last decade, a greater focus has been given to impact of genetic variation in membrane transporters on the pharmacokinetics and toxicity of numerous therapeutic drugs. While the majority of transporter-related pharmacogenetic research has been in regards to classic genes encoding the outward-directed ATP-binding cassette (ABC) transporters, such as ABCB1 (Pglycoprotein), ABCC2 (MRP2), and ABCG2 (BCRP), more studies have been conducted in recent years evaluating genes encoding solute carriers (SLC) that mediate the cellular uptake of drugs, such as SLCO1B1 (OATP1B1) and SLC22A1 (OCT1). The distribution of ABC and SLC transporters in tissues key to pharmacokinetics, such as intestine (absorption), blood-brain-barrier (distribution), liver (metabolism), and kidneys (excretion), strongly suggests that genetic variation associated with changes in protein expression or function of these transporters may have a substantial impact on systemic drug exposure and toxicity. In this current article, we will review recent advances in understanding the contribution of critical ABC and SLC transporters to interindividual pharmacokinetic and dynamic variability of substrate drugs.
Export Options
About this article
Cite this article as:
Franke M. R., Gardner R. E. and Sparreboom A., Pharmacogenetics of Drug Transporters, Current Pharmaceutical Design 2010; 16 (2) . https://dx.doi.org/10.2174/138161210790112683
DOI https://dx.doi.org/10.2174/138161210790112683 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolomics and Heart Diseases: From Basic to Clinical Approach
Current Medicinal Chemistry New Treatments for COPD in the Elderly
Current Pharmaceutical Design Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design The Emerging Roles of Extracellular Vesicles in Ovarian Cancer
Current Drug Metabolism The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Noninvasive Mechanical Ventilation in the Treatment of Community-Acquired Pneumonia
Current Respiratory Medicine Reviews The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Current Pharmaceutical Design Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Current Drug Targets Effective Agents Targeting the Mitochondria and Apoptosis to Protect the Heart
Current Pharmaceutical Design